Granulomatosis With Polyangiitis Treatment Market Report 2026

The granulomatosis with polyangiitis treatment market size has grown strongly in recent years. It will grow from $2.55 billion in 2025 to $2.75 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to autoimmune disease recognition, corticosteroid availability, hospital nephrology services, immunosuppressive drug use, diagnostic imaging adoption.

The granulomatosis with polyangiitis treatment market size is expected to see strong growth in the next few years. It will grow to $3.69 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to biologic drug innovation, precision autoimmune treatment, early diagnostic screening, chronic disease management demand, specialty clinic growth. Major trends in the forecast period include increased use of biologic therapies, rising demand for early autoimmune diagnosis, expansion of long-term disease remission strategies, growth of combination immunosuppressive therapies, improved monitoring of organ damage.

The rising prevalence of autoimmune diseases is expected to drive the growth of the granulomatosis with polyangiitis treatment market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks healthy cells and tissues, causing inflammation and damage to various organs. The increase in autoimmune diseases is linked to environmental triggers, such as infections, chemicals, or pollutants, as well as lifestyle changes. Treatments for granulomatosis with polyangiitis help manage autoimmune diseases by using immunosuppressive therapies like corticosteroids and cyclophosphamide, which control inflammation and prevent organ damage. Early intervention and personalized treatment are essential for managing other autoimmune conditions with similar mechanisms. For example, in June 2023, according to the Office for National Statistics, a UK-based government department, the global population of people with multiple sclerosis (MS), an autoimmune disease, reached 2.9 million, up from 2.8 million in 2022. Therefore, the rising prevalence of autoimmune diseases is fueling growth in the granulomatosis with polyangiitis treatment market.

The increasing healthcare expenditure is expected to support the growth of the granulomatosis with polyangiitis treatment market going forward. Healthcare expenditure refers to the total financial resources spent by individuals, organizations, or governments on preventing, treating, and managing health conditions. Rising healthcare spending is driven by advancements in medical technology, as new diagnostic tools, treatments, and innovative therapies often come at higher costs, contributing to overall increases in healthcare spending. Higher healthcare expenditure facilitates advancements in granulomatosis with polyangiitis treatment by enabling greater investment in early diagnosis, access to advanced immunosuppressive and biologic therapies, and enhanced patient management infrastructure. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency administering Medicare and Medicaid programs, U.S. healthcare expenditures increased by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per individual. Therefore, rising healthcare expenditure is driving the growth of the granulomatosis with polyangiitis treatment market.

Key companies in the granulomatosis with polyangiitis treatment market are focusing on developing innovative therapies, such as oral corticosteroids, to provide patients with more effective treatment options that improve disease management while reducing long-term steroid side effects. Oral corticosteroids are medications that reduce inflammation and suppress the immune system, commonly used to treat allergies, autoimmune diseases, and inflammatory disorders. For instance, in October 2024, AstraZeneca plc, a UK-based pharmaceutical company, announced that Fasenra (bevacizumab) had been approved in the European Union as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). This approval follows positive results from the MANDARA Phase III trial, which demonstrated Fasenra’s effectiveness in achieving remission and reducing reliance on oral corticosteroids in EGPA patients.

Major companies operating in the granulomatosis with polyangiitis treatment market are Pfizer Inc., F Hoffmann La Roche Ltd, Sanofi S A, GlaxoSmithKline plc, Amgen Inc, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc, ChemoCentryx Inc, Medac Pharma Inc, InflaRx GmbH, AbbVie Inc, Johnson & Johnson, Bristol Myers Squibb Company, Novartis AG, Biogen Inc, Takeda Pharmaceutical Company Limited, UCB S A, Bayer AG, Merck & Co Inc, Eli Lilly and Company, Astellas Pharma Inc.

North America was the largest region in the granulomatosis with polyangiitis treatment market in 2025. The regions covered in the granulomatosis with polyangiitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the granulomatosis with polyangiitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the granulomatosis with polyangiitis treatment market by increasing costs of imported biologics, immunosuppressive drugs, and diagnostic equipment. Hospitals and specialty clinics are most affected due to dependence on imported therapies. These tariffs raise treatment costs by increasing expenses for advanced immunomodulatory therapy and diagnostic monitoring, potentially limiting access in rare autoimmune disease care. However, they encourage domestic pharmaceutical manufacturing, supporting local production of immunosuppressive drugs and diagnostics.

The granulomatosis with polyangiitis treatment market research report is one of a series of new reports that provides granulomatosis with polyangiitis treatment market statistics, including granulomatosis with polyangiitis treatment industry global market size, regional shares, competitors with a granulomatosis with polyangiitis treatment market share, detailed granulomatosis with polyangiitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the granulomatosis with polyangiitis treatment industry. This granulomatosis with polyangiitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Granulomatosis with polyangiitis (GPA) treatment involves the use of medications to control inflammation, suppress the immune system, and prevent organ damage. GPA is a rare autoimmune disorder that causes inflammation of small to medium blood vessels, leading to restricted blood flow and tissue injury, particularly in the respiratory tract and kidneys. Treatment primarily includes immunosuppressive therapies, such as corticosteroids and biologics, to reduce inflammation and protect organ function.

The main drug types for granulomatosis with polyangiitis treatment are steroids, immunosuppressants, and others. Steroids are anti-inflammatory medications that reduce swelling and suppress the immune system. In GPA, they are often used alongside other drugs to manage symptoms. Treatments include immunosuppressants and corticosteroids, administered via oral or intravenous routes. These medications are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by various end users, including hospitals, home care providers, specialty clinics, and others.

The granulomatosis with polyangiitis treatment market includes sales of symptomatic treatment, monoclonal antibodies, and plasmapheresis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.